Category Archives: Warning Letters

OPDP Makes a Point on Risk Info and DTC (Updated)

The Office of Prescription Drug Promotion (OPDP) has been particularly low-key this year when it comes to visible enforcement actions expressed through the issuance of Warning or Untitled letters. Up until this week, the office had issued only 5 letters … Continue reading

Posted in Warning Letters | 1 Comment

Weekly Roundup 11.4.16

We are almost through it!  Just a few more days. In the meantime, the more enjoyable aspects of autumn, chilly nights, fires in the fireplace, and brilliant leaves are all upon us. Soon the end of year holidays will be … Continue reading

Posted in Warning Letters, Weekly Roundup | 1 Comment

The Drop in OPDP Enforcement

Back when the Office of Prescription Drug Promotion (OPDP) issued regulatory action letters on a regular basis (either Warning Letters or Untitled Letters) regarding what the agency saw as infractions in the course of promotional speech, I would post a … Continue reading

Posted in Warning Letters | Comments Off on The Drop in OPDP Enforcement

Testimonials – The Pitfalls

People like to get information from people they trust. Moreover, a hallmark of digital communications has been a turning away from large, institutionalized sources for information and turning instead to hear from individuals. Pew Research has shown that especially for … Continue reading

Posted in FDA Policy, Warning Letters | Comments Off on Testimonials – The Pitfalls

Socializing Medicine – FDA Enforcement Involving Social Media

Have you ever had a conversation with someone who said pharma needs to stay away from social media because it is too risky? Even today, some hold that opinion. When social media, used primarily by individuals in its nascent stage, … Continue reading

Posted in Social Media, Warning Letters | Comments Off on Socializing Medicine – FDA Enforcement Involving Social Media